Deferred Income Tax Expense (Benefit) of Keenova Therapeutics plc from 30 Sep 2011 to 27 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Keenova Therapeutics plc annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 30 Sep 2011 to 27 Dec 2024.
  • Keenova Therapeutics plc Deferred Income Tax Expense (Benefit) for the quarter ending 29 Dec 2023 was $6,600,000.
  • Keenova Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2024 was $158,700,000.
  • Keenova Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2021 was $59,900,000, a 116% decline from 2020.
  • Keenova Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2020 was $384,200,000.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

Keenova Therapeutics plc Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $158,700,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $59,900,000 -$444,100,000 -116% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $384,200,000 +$990,300,000 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $606,100,000 -$63,200,000 -12% 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $542,900,000 +$1,204,800,000 +69% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $1,747,700,000 -$1,371,300,000 -364% 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $376,400,000 -$179,600,000 -91% 26 Sep 2015 30 Sep 2016 10-K 26 Feb 2019 2018 FY
2015 $196,800,000 -$143,000,000 -266% 27 Sep 2014 25 Sep 2015 10-K 27 Feb 2018 2017 FY
2014 $53,800,000 -$39,900,000 -287% 28 Sep 2013 26 Sep 2014 10-K 29 Nov 2016 2016 FY
2013 $13,900,000 -$22,900,000 -254% 29 Sep 2012 27 Sep 2013 10-K 24 Nov 2015 2015 FY
2012 $9,000,000 -$27,400,000 -75% 01 Oct 2011 28 Sep 2012 8-K 03 Apr 2015 2014 FY
2011 $36,400,000 25 Sep 2010 30 Sep 2011 10-K 13 Dec 2013 2013 FY

Keenova Therapeutics plc Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2023 $6,600,000 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $0 +$4,400,000 29 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $508,900,000 +$515,300,000 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $33,400,000 -$32,500,000 -3611% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q3 2022 $4,400,000 -$10,200,000 -176% 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $6,400,000 -$16,300,000 -165% 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q2 2022 $472,500,000 -$482,400,000 -4873% 16 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $900,000 -$4,300,000 -126% 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $79,000,000 -$141,700,000 -226% 31 Dec 2021 10-K 26 Mar 2024 2023 FY
Q3 2021 $5,800,000 -$4,400,000 -43% 24 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $9,900,000 -$297,900,000 -97% 25 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,400,000 -$100,000 -2.9% 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $62,700,000 +$972,800,000 25 Dec 2020 10-K 03 Mar 2023 2022 FY
Q3 2020 $10,200,000 -$20,700,000 -67% 25 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $307,800,000 +$277,900,000 +929% 26 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $3,500,000 -$239,700,000 -99% 27 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $910,100,000 -$601,000,000 -194% 27 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $30,900,000 +$162,300,000 27 Sep 2019 10-Q 03 Nov 2020 2020 Q2
Q2 2019 $29,900,000 +$84,500,000 28 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $243,200,000 +$291,000,000 29 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $309,100,000 +$1,298,800,000 +81% 28 Dec 2018 10-K 10 Mar 2021 2020 FY
Q3 2018 $131,400,000 -$155,000,000 -657% 28 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $54,600,000 +$32,900,000 +38% 29 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $47,800,000 +$28,100,000 +37% 30 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $1,607,900,000 -$1,404,200,000 -689% 29 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $23,600,000 +$117,900,000 29 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $87,500,000 +$12,400,000 +12% 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $75,900,000 +$34,100,000 +31% 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $203,700,000 -$94,800,000 -87% 30 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $94,300,000 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $99,900,000 24 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $110,000,000 25 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $108,900,000 -$39,200,000 -56% 25 Dec 2015 10-QT 07 Feb 2017 2016 Q4
Q4 2014 $69,700,000 -$84,700,000 -565% 26 Dec 2014 10-Q 02 Feb 2016 2016 Q1
Q4 2013 $15,000,000 +$13,400,000 +838% 27 Dec 2013 10-Q 03 Feb 2015 2015 Q1
Q4 2012 $1,600,000 28 Dec 2012 10-Q 07 Feb 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.